Public health officials are monitoring a new strain of COVID-19 that is currently spreading across the United States. The variant, technically designated as BA.3.2 and nicknamed “Cicada,” has emerged as a significant point of interest for epidemiologists due to its unusual pattern of appearance and its potential impact on existing immunity.
The COVID-19 Cicada variant spreading throughout the country has been identified in at least 25 states, including Kentucky. While the virus has been circulating for some time, its sudden increase in prevalence has drawn comparisons to the insect for which We see named—remaining dormant or “underground” before rapidly surfacing in the general population.
According to data from the Centers for Disease Control and Prevention (CDC), the variant was first detected in South Africa in November 2024. After a period of low-level circulation, the CDC reports that cases began to increase in September 2025. Since February 11, the strain has been reported in 23 different countries.
As a board-certified physician, I have seen how the evolution of viral structures can complicate public health responses. With Cicada, the primary concern is not necessarily a shift in the clinical presentation of the disease, but rather how the virus’s mutations might interact with the antibodies generated by previous infections and vaccinations.
Understanding the BA.3.2 Mutation
The Cicada variant is a mutation of the virus that retains many of the characteristics of previous strains but possesses a slightly altered structure. Dr. Jeff Foxx, a retired family physician, notes that while the variant is not identical to its predecessors, it shares similar traits. The critical question for medical professionals is whether these structural changes allow the virus to better evade the immune system.
Current evidence suggests that while the mutation may make some vaccinations less effective for certain individuals, they still provide a layer of protection. Dr. Foxx explains that the structure has changed slightly, but the practical impact is still being determined. He suggests that patients will likely still derive benefit from vaccines, even if that benefit is not as robust as it was with earlier versions of the virus.
The exact level of contagiousness for BA.3.2 remains unknown. Because the variant is still in the early stages of widespread domestic spread, researchers are working to determine if it transmits more efficiently than the strains that preceded it.
Who is Most at Risk?
While COVID-19 continues to be a threat to the general population, health professionals have identified specific groups who may be more vulnerable to this particular strain. Notably, children are currently considered the most at risk for the Cicada variant.
Beyond pediatric concerns, the traditional high-risk categories remain vulnerable. This includes the elderly and those who are immunocompromised, as their bodies may struggle more significantly to mount an effective defense against a mutated strain that can potentially bypass some existing antibodies.
For those in these high-risk groups, the recommended preventative measures remain consistent with established public health guidance. Dr. Foxx advises that individuals at risk should consider wearing masks in crowded settings, practicing frequent handwashing, and avoiding large crowds to minimize exposure.
Recognizing the Symptoms
For those attempting to distinguish a Cicada infection from a common cold or other respiratory illnesses, the symptoms remain largely consistent with previous COVID-19 iterations. Key indicators to watch for include:
- Sore throat
- Persistent cough
- Fever
- Shortness of breath
Because these symptoms overlap with many other seasonal viruses, testing is the only definitive way to confirm the presence of the BA.3.2 variant.
Timeline of the Cicada Variant’s Emergence
The trajectory of the Cicada variant highlights the global nature of viral evolution and the speed at which new strains can migrate across borders.
| Date | Event/Milestone | Location |
|---|---|---|
| November 2024 | Initial detection of the variant | South Africa |
| September 2025 | Observed increase in cases | Global/Regional |
| February 11, 2026 | Reported presence in 23 countries | International |
| Current Period | Detected in 25+ U.S. States | United States |
Practical Steps for Prevention and Management
The emergence of the COVID-19 Cicada variant spreading throughout the country serves as a reminder that the virus remains an active public health challenge. Dr. Foxx emphasizes that regardless of the specific variant or the “nickname” attached to it, the fundamental nature of the disease remains infectious and potentially dangerous.
The primary recommendation for the public is to prioritize testing at the first sign of symptoms. Early detection not only allows for faster treatment but prevents the further spread of the mutation within the community. For those who are hesitant about the effectiveness of older vaccines, consulting with a primary care provider about the most current boosters is the most reliable path forward.
It is also worth noting that COVID-19 often follows a seasonal pattern. Spikes in cases are common during both the winter and summer months, and the current spread of the Cicada variant may be coinciding with these typical seasonal fluctuations.
Disclaimer: This article is provided for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
Public health agencies continue to sequence genomes from positive cases to better understand the mutation rate of BA.3.2. The next critical checkpoint will be the release of updated CDC surveillance reports, which will provide a clearer picture of the variant’s prevalence and its impact on hospitalization rates across the 25 affected states.
We invite you to share your thoughts or questions about the current health landscape in the comments below.
